#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


1-1	0-13	Resting-State	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
1-2	14-26	Connectivity	_
1-3	27-37	Biomarkers	_
1-4	38-40	of	_
1-5	41-50	Cognitive	_
1-6	51-62	Performance	_
1-7	63-66	and	_
1-8	67-73	Social	_
1-9	74-82	Function	_
1-10	83-85	in	_
1-11	86-99	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
1-12	100-108	Spectrum	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
1-13	109-118	Disorders	http://maven.renci.org/NeuroBridge/neurobridge#AutismSpectrumDisorder
1-14	119-122	and	_
1-15	123-130	Healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
1-16	131-139	Controls	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
1-17	140-150	Background	_
1-18	151-159	Deficits	_
1-19	160-162	in	_
1-20	163-177	neurocognition	_
1-21	178-181	and	_
1-22	182-188	social	_
1-23	189-198	cognition	_
1-24	199-202	are	_
1-25	203-210	drivers	_
1-26	211-213	of	_
1-27	214-221	reduced	_
1-28	222-233	functioning	_
1-29	234-236	in	_
1-30	237-250	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#SchizophrenicDisorders
1-31	251-259	spectrum	http://maven.renci.org/NeuroBridge/neurobridge#SchizophrenicDisorders
1-32	260-269	disorders	http://maven.renci.org/NeuroBridge/neurobridge#SchizophrenicDisorders
1-33	270-271	(	http://maven.renci.org/NeuroBridge/neurobridge#SchizophrenicDisorders
1-34	272-276	SSDs	http://maven.renci.org/NeuroBridge/neurobridge#SchizophrenicDisorders
1-35	277-278	)	http://maven.renci.org/NeuroBridge/neurobridge#SchizophrenicDisorders
1-36	279-280	,	_
1-37	281-285	with	_
1-38	286-297	potentially	_
1-39	298-304	shared	_
1-40	305-320	neurobiological	_
1-41	321-334	underpinnings	_
1-42	335-336	.	_

2-1	337-341	Many	_
2-2	342-349	studies	_
2-3	350-354	have	_
2-4	355-361	sought	_
2-5	362-364	to	_
2-6	365-373	identify	_
2-7	374-385	brain-based	_
2-8	386-396	biomarkers	_
2-9	397-399	of	_
2-10	400-405	these	_
2-11	406-414	clinical	_
2-12	415-424	variables	_
2-13	425-430	using	_
2-14	431-432	a	_
2-15	433-439	priori	_
2-16	440-451	dichotomies	_
2-17	452-453	(	_
2-18	454-458	i.e.	_
2-19	459-460	,	_
2-20	461-465	good	_
2-21	466-469	vs.	_
2-22	470-474	poor	_
2-23	475-484	cognition	_
2-24	485-486	,	_
2-25	487-494	deficit	_
2-26	495-498	vs.	_
2-27	499-509	nondeficit	_
2-28	510-518	syndrome	_
2-29	519-520	)	_
2-30	521-522	.	_

3-1	523-530	Methods	_
3-2	531-533	We	_
3-3	534-543	evaluated	_
3-4	544-545	a	_
3-5	546-551	fully	_
3-6	552-563	data-driven	_
3-7	564-572	approach	_
3-8	573-575	to	_
3-9	576-578	do	_
3-10	579-582	the	_
3-11	583-587	same	_
3-12	588-590	by	_
3-13	591-599	building	_
3-14	600-603	and	_
3-15	604-614	validating	_
3-16	615-616	a	_
3-17	617-641	brain-connectivity-based	_
3-18	642-651	biomarker	_
3-19	652-654	of	_
3-20	655-661	social	_
3-21	662-671	cognitive	_
3-22	672-675	and	_
3-23	676-690	neurocognitive	_
3-24	691-702	performance	_
3-25	703-705	in	_
3-26	706-707	a	_
3-27	708-714	sample	_
3-28	715-720	using	_
3-29	721-728	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
3-30	729-734	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
3-31	735-738	and	_
3-32	739-749	task-based	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
3-33	750-754	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
3-34	755-756	(	_
3-35	757-765	n=75/133	_
3-36	766-773	healthy	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-37	774-787	controls/SSDs	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
3-38	788-789	,	_
3-39	790-793	188	_
3-40	794-799	total	_
3-41	800-801	)	_
3-42	802-803	.	_

4-1	804-806	We	_
4-2	807-811	used	_
4-3	812-821	canonical	_
4-4	822-833	correlation	_
4-5	834-842	analysis	_
4-6	843-851	followed	_
4-7	852-854	by	_
4-8	855-865	clustering	_
4-9	866-868	to	_
4-10	869-877	identify	_
4-11	878-879	a	_
4-12	880-890	functional	_
4-13	891-903	connectivity	_
4-14	904-913	signature	_
4-15	914-916	of	_
4-16	917-923	normal	_
4-17	924-927	and	_
4-18	928-945	poorly-performing	_
4-19	946-952	social	_
4-20	953-962	cognitive	_
4-21	963-966	and	_
4-22	967-981	neurocognitive	_
4-23	982-993	performance	_
4-24	994-995	.	_

5-1	996-1003	Results	_
5-2	1004-1009	Those	_
5-3	1010-1014	with	_
5-4	1015-1019	poor	_
5-5	1020-1026	social	_
5-6	1027-1036	cognitive	_
5-7	1037-1040	and	_
5-8	1041-1055	neurocognitive	_
5-9	1056-1067	performance	_
5-10	1068-1072	were	_
5-11	1073-1087	differentiated	_
5-12	1088-1092	from	_
5-13	1093-1098	those	_
5-14	1099-1103	with	_
5-15	1104-1110	normal	_
5-16	1111-1122	performance	_
5-17	1123-1125	by	_
5-18	1126-1133	greater	_
5-19	1134-1147	resting-state	_
5-20	1148-1160	connectivity	_
5-21	1161-1163	in	_
5-22	1164-1167	the	_
5-23	1168-1174	mirror	_
5-24	1175-1181	neuron	_
5-25	1182-1185	and	_
5-26	1186-1197	mentalizing	_
5-27	1198-1205	systems	_
5-28	1206-1207	.	_

6-1	1208-1210	We	_
6-2	1211-1220	validated	_
6-3	1221-1224	our	_
6-4	1225-1233	findings	_
6-5	1234-1236	by	_
6-6	1237-1244	showing	_
6-7	1245-1249	that	_
6-8	1250-1265	poor-performers	_
6-9	1266-1270	also	_
6-10	1271-1277	scored	_
6-11	1278-1283	lower	_
6-12	1284-1286	on	_
6-13	1287-1297	functional	_
6-14	1298-1305	outcome	_
6-15	1306-1314	measures	_
6-16	1315-1318	not	_
6-17	1319-1327	included	_
6-18	1328-1330	in	_
6-19	1331-1334	the	_
6-20	1335-1343	original	_
6-21	1344-1352	analysis	_
6-22	1353-1354	,	_
6-23	1355-1358	and	_
6-24	1359-1372	demonstrating	_
6-25	1373-1388	neuroanatomical	_
6-26	1389-1400	differences	_
6-27	1401-1408	between	_
6-28	1409-1412	the	_
6-29	1413-1419	normal	_
6-30	1420-1423	and	_
6-31	1424-1441	poorly-performing	_
6-32	1442-1448	groups	_
6-33	1449-1450	.	_

7-1	1451-1453	We	_
7-2	1454-1458	used	_
7-3	1459-1460	a	_
7-4	1461-1468	support	_
7-5	1469-1475	vector	_
7-6	1476-1483	machine	_
7-7	1484-1494	classifier	_
7-8	1495-1497	to	_
7-9	1498-1509	demonstrate	_
7-10	1510-1514	that	_
7-11	1515-1525	functional	_
7-12	1526-1538	connectivity	_
7-13	1539-1544	alone	_
7-14	1545-1547	is	_
7-15	1548-1554	enough	_
7-16	1555-1557	to	_
7-17	1558-1569	distinguish	_
7-18	1570-1576	normal	_
7-19	1577-1580	and	_
7-20	1581-1598	poorly-performing	_
7-21	1599-1607	subjects	_
7-22	1608-1609	,	_
7-23	1610-1613	and	_
7-24	1614-1624	replicated	_
7-25	1625-1628	our	_
7-26	1629-1637	findings	_
7-27	1638-1640	in	_
7-28	1641-1643	an	_
7-29	1644-1655	independent	_
7-30	1656-1662	sample	_
7-31	1663-1664	(	_
7-32	1665-1669	n=75	_
7-33	1670-1675	total	_
7-34	1676-1677	)	_
7-35	1678-1679	.	_

8-1	1680-1691	Conclusions	_
8-2	1692-1693	A	_
8-3	1694-1699	brief	_
8-4	1700-1704	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-5	1705-1709	scan	_
8-6	1710-1713	may	_
8-7	1714-1724	ultimately	_
8-8	1725-1727	be	_
8-9	1728-1734	useful	_
8-10	1735-1737	in	_
8-11	1738-1744	future	_
8-12	1745-1752	studies	_
8-13	1753-1758	aimed	_
8-14	1759-1761	at	_
8-15	1762-1776	characterizing	_
8-16	1777-1781	long	_
8-17	1782-1786	term	_
8-18	1787-1794	illness	_
8-19	1795-1807	trajectories	_
8-20	1808-1809	,	_
8-21	1810-1813	and	_
8-22	1814-1824	treatments	_
8-23	1825-1829	that	_
8-24	1830-1836	target	_
8-25	1837-1845	specific	_
8-26	1846-1851	brain	_
8-27	1852-1861	circuitry	_
8-28	1862-1864	in	_
8-29	1865-1870	those	_
8-30	1871-1875	with	_
8-31	1876-1884	impaired	_
8-32	1885-1894	cognition	_
8-33	1895-1898	and	_
8-34	1899-1907	function	_
8-35	1908-1909	.	_

9-1	1910-1917	Methods	_
9-2	1918-1920	We	_
9-3	1921-1929	analyzed	_
9-4	1930-1941	participant	_
9-5	1942-1946	data	_
9-6	1947-1951	from	_
9-7	1952-1955	the	_
9-8	1956-1961	three	_
9-9	1962-1966	site	_
9-10	1967-1973	Social	_
9-11	1974-1983	Processes	_
9-12	1984-1994	Initiative	_
9-13	1995-1997	in	_
9-14	1998-2010	Neurobiology	_
9-15	2011-2013	of	_
9-16	2014-2017	the	_
9-17	2018-2031	Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
9-18	2032-2033	(	_
9-19	2034-2035	s	_
9-20	2036-2037	)	_
9-21	2038-2039	(	_
9-22	2040-2045	SPINS	_
9-23	2046-2047	)	_
9-24	2048-2053	study	_
9-25	2054-2055	(	_
9-26	2056-2061	n=188	_
9-27	2062-2063	,	_
9-28	2064-2077	age=33.0±10.2	_
9-29	2078-2083	years	_
9-30	2084-2085	;	_
9-31	2086-2093	SSD=133	_
9-32	2094-2095	,	_
9-33	2096-2109	age=34.1±10.1	_
9-34	2110-2111	;	_
9-35	2112-2123	controls=75	_
9-36	2124-2125	,	_
9-37	2126-2139	age=31.3±10.1	_
9-38	2140-2141	)	_
9-39	2142-2143	.	_

10-1	2144-2156	Demographics	_
10-2	2157-2160	are	_
10-3	2161-2171	summarized	_
10-4	2172-2174	in	_
10-5	2175-2180	table	_
10-6	2181-2182	1	_
10-7	2183-2184	,	_
10-8	2185-2188	see	_
10-9	2189-2194	table	_
10-10	2195-2197	s5	_
10-11	2198-2201	for	_
10-12	2202-2214	demographics	_
10-13	2215-2217	at	_
10-14	2218-2222	each	_
10-15	2223-2227	site	_
10-16	2228-2233	split	_
10-17	2234-2236	by	_
10-18	2237-2246	diagnosis	_
10-19	2247-2248	.	_

11-1	2249-2252	See	_
11-2	2253-2263	supplement	_
11-3	2264-2267	for	_
11-4	2268-2287	inclusion/exclusion	_
11-5	2288-2296	criteria	_
11-6	2297-2298	.	_

12-1	2299-2302	All	_
12-2	2303-2315	participants	_
12-3	2316-2322	signed	_
12-4	2323-2325	an	_
12-5	2326-2334	informed	_
12-6	2335-2342	consent	_
12-7	2343-2352	agreement	_
12-8	2353-2356	and	_
12-9	2357-2360	the	_
12-10	2361-2366	study	_
12-11	2367-2370	was	_
12-12	2371-2379	approved	_
12-13	2380-2382	by	_
12-14	2383-2396	institutional	_
12-15	2397-2403	ethics	_
12-16	2404-2410	boards	_
12-17	2411-2413	at	_
12-18	2414-2417	all	_
12-19	2418-2431	participating	_
12-20	2432-2444	institutions	_
12-21	2445-2446	.	_

13-1	2447-2450	All	_
13-2	2451-2463	participants	_
13-3	2464-2473	completed	_
13-4	2474-2482	multiple	_
13-5	2483-2494	assessments	_
13-6	2495-2498	out	_
13-7	2499-2501	of	_
13-8	2502-2505	the	_
13-9	2506-2509	MRI	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
13-10	2510-2517	scanner	_
13-11	2518-2519	.	_

14-1	2520-2525	SC/NC	http://maven.renci.org/NeuroBridge/neurobridge#Thing
14-2	2526-2537	functioning	_
14-3	2538-2541	was	_
14-4	2542-2550	assessed	_
14-5	2551-2554	via	_
14-6	2555-2558	the	_
14-7	2559-2563	Penn	http://maven.renci.org/NeuroBridge/neurobridge#PennEmotionRecognitionTask
14-8	2564-2571	Emotion	http://maven.renci.org/NeuroBridge/neurobridge#PennEmotionRecognitionTask
14-9	2572-2583	Recognition	http://maven.renci.org/NeuroBridge/neurobridge#PennEmotionRecognitionTask
14-10	2584-2588	Task	http://maven.renci.org/NeuroBridge/neurobridge#PennEmotionRecognitionTask
14-11	2589-2590	(	http://maven.renci.org/NeuroBridge/neurobridge#PennEmotionRecognitionTask
14-12	2591-2595	ER40	http://maven.renci.org/NeuroBridge/neurobridge#PennEmotionRecognitionTask
14-13	2596-2597	)	http://maven.renci.org/NeuroBridge/neurobridge#PennEmotionRecognitionTask
14-14	2598-2599	,	_
14-15	2600-2607	Reading	http://maven.renci.org/NeuroBridge/neurobridge#ReadingtheMindintheEyesTest
14-16	2608-2611	the	http://maven.renci.org/NeuroBridge/neurobridge#ReadingtheMindintheEyesTest
14-17	2612-2616	Mind	http://maven.renci.org/NeuroBridge/neurobridge#ReadingtheMindintheEyesTest
14-18	2617-2619	in	http://maven.renci.org/NeuroBridge/neurobridge#ReadingtheMindintheEyesTest
14-19	2620-2623	the	http://maven.renci.org/NeuroBridge/neurobridge#ReadingtheMindintheEyesTest
14-20	2624-2628	Eyes	http://maven.renci.org/NeuroBridge/neurobridge#ReadingtheMindintheEyesTest
14-21	2629-2633	Test	http://maven.renci.org/NeuroBridge/neurobridge#ReadingtheMindintheEyesTest
14-22	2634-2635	(	http://maven.renci.org/NeuroBridge/neurobridge#ReadingtheMindintheEyesTest
14-23	2636-2640	RMET	http://maven.renci.org/NeuroBridge/neurobridge#ReadingtheMindintheEyesTest
14-24	2641-2642	)	http://maven.renci.org/NeuroBridge/neurobridge#ReadingtheMindintheEyesTest
14-25	2643-2644	,	_
14-26	2645-2658	Relationships	http://maven.renci.org/NeuroBridge/neurobridge#CorrelationMeasure
14-27	2659-2665	Across	http://maven.renci.org/NeuroBridge/neurobridge#CorrelationMeasure
14-28	2666-2673	Domains	http://maven.renci.org/NeuroBridge/neurobridge#CorrelationMeasure
14-29	2674-2675	(	http://maven.renci.org/NeuroBridge/neurobridge#CorrelationMeasure
14-30	2676-2679	RAD	http://maven.renci.org/NeuroBridge/neurobridge#CorrelationMeasure
14-31	2680-2681	)	http://maven.renci.org/NeuroBridge/neurobridge#CorrelationMeasure
14-32	2682-2683	,	_
14-33	2684-2687	the	_
14-34	2688-2693	three	_
14-35	2694-2700	scales	_
14-36	2701-2705	from	_
14-37	2706-2709	the	_
14-38	2710-2719	Awareness	http://maven.renci.org/NeuroBridge/neurobridge#AwarenessofSocialInferenceTestRevised
14-39	2720-2722	of	http://maven.renci.org/NeuroBridge/neurobridge#AwarenessofSocialInferenceTestRevised
14-40	2723-2729	Social	http://maven.renci.org/NeuroBridge/neurobridge#AwarenessofSocialInferenceTestRevised
14-41	2730-2739	Inference	http://maven.renci.org/NeuroBridge/neurobridge#AwarenessofSocialInferenceTestRevised
14-42	2740-2744	Test	http://maven.renci.org/NeuroBridge/neurobridge#AwarenessofSocialInferenceTestRevised
14-43	2745-2752	Revised	http://maven.renci.org/NeuroBridge/neurobridge#AwarenessofSocialInferenceTestRevised
14-44	2753-2754	(	http://maven.renci.org/NeuroBridge/neurobridge#AwarenessofSocialInferenceTestRevised
14-45	2755-2760	TASIT	http://maven.renci.org/NeuroBridge/neurobridge#AwarenessofSocialInferenceTestRevised
14-46	2761-2762	)	http://maven.renci.org/NeuroBridge/neurobridge#AwarenessofSocialInferenceTestRevised
14-47	2763-2764	,	_
14-48	2765-2768	and	_
14-49	2769-2772	six	_
14-50	2773-2787	neurocognitive	_
14-51	2788-2795	domains	_
14-52	2796-2798	of	_
14-53	2799-2802	the	_
14-54	2803-2810	MATRICS	http://maven.renci.org/NeuroBridge/neurobridge#PediatricSleepQuestionnaire
14-55	2811-2812	.	_

15-1	2813-2819	Social	_
15-2	2820-2831	functioning	_
15-3	2832-2835	and	_
15-4	2836-2843	quality	_
15-5	2844-2846	of	_
15-6	2847-2851	life	_
15-7	2852-2855	was	_
15-8	2856-2864	assessed	_
15-9	2865-2868	via	_
15-10	2869-2872	the	_
15-11	2873-2882	Birchwood	http://maven.renci.org/NeuroBridge/neurobridge#BirchwoodSocialFunctioningScale
15-12	2883-2889	Social	http://maven.renci.org/NeuroBridge/neurobridge#BirchwoodSocialFunctioningScale
15-13	2890-2901	Functioning	http://maven.renci.org/NeuroBridge/neurobridge#BirchwoodSocialFunctioningScale
15-14	2902-2907	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BirchwoodSocialFunctioningScale
15-15	2908-2909	(	http://maven.renci.org/NeuroBridge/neurobridge#BirchwoodSocialFunctioningScale
15-16	2910-2914	BSFS	http://maven.renci.org/NeuroBridge/neurobridge#BirchwoodSocialFunctioningScale
15-17	2915-2916	)	http://maven.renci.org/NeuroBridge/neurobridge#BirchwoodSocialFunctioningScale
15-18	2917-2920	and	_
15-19	2921-2928	Quality	http://maven.renci.org/NeuroBridge/neurobridge#QualityofLifeScale
15-20	2929-2931	of	http://maven.renci.org/NeuroBridge/neurobridge#QualityofLifeScale
15-21	2932-2936	Life	http://maven.renci.org/NeuroBridge/neurobridge#QualityofLifeScale
15-22	2937-2942	Scale	http://maven.renci.org/NeuroBridge/neurobridge#QualityofLifeScale
15-23	2943-2944	(	http://maven.renci.org/NeuroBridge/neurobridge#QualityofLifeScale
15-24	2945-2948	QLS	http://maven.renci.org/NeuroBridge/neurobridge#QualityofLifeScale
15-25	2949-2950	)	http://maven.renci.org/NeuroBridge/neurobridge#QualityofLifeScale
15-26	2951-2952	.	_

16-1	2953-2964	Psychiatric	_
16-2	2965-2972	symptom	_
16-3	2973-2979	burden	_
16-4	2980-2983	was	_
16-5	2984-2992	assessed	_
16-6	2993-2996	via	_
16-7	2997-3000	the	_
16-8	3001-3006	Brief	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
16-9	3007-3018	Psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
16-10	3019-3025	Rating	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
16-11	3026-3031	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
16-12	3032-3033	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
16-13	3034-3038	BPRS	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
16-14	3039-3040	)	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
16-15	3041-3044	and	_
16-16	3045-3050	Scale	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
16-17	3051-3054	for	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
16-18	3055-3058	the	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
16-19	3059-3069	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
16-20	3070-3072	of	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
16-21	3073-3081	Negative	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
16-22	3082-3090	Symptoms	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
16-23	3091-3092	(	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
16-24	3093-3097	SANS	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
16-25	3098-3099	)	http://maven.renci.org/NeuroBridge/neurobridge#ScaleforAssessmentofNegativeSymptoms
16-26	3100-3101	.	_

17-1	3102-3105	Two	_
17-2	3106-3116	additional	_
17-3	3117-3127	SANS-based	_
17-4	3128-3136	measures	_
17-5	3137-3139	of	_
17-6	3140-3150	diminished	_
17-7	3151-3160	emotional	_
17-8	3161-3171	expression	_
17-9	3172-3175	and	_
17-10	3176-3180	poor	_
17-11	3181-3191	motivation	_
17-12	3192-3196	were	_
17-13	3197-3205	included	_
17-14	3206-3208	as	_
17-15	3209-3213	they	_
17-16	3214-3220	relate	_
17-17	3221-3223	to	_
17-18	3224-3234	functional	_
17-19	3235-3243	outcomes	_
17-20	3244-3246	in	_
17-21	3247-3250	SSD	http://maven.renci.org/NeuroBridge/neurobridge#AcuteStressDisorder
17-22	3251-3252	.	_

18-1	3253-3267	Extrapyramidal	_
18-2	3268-3276	symptoms	_
18-3	3277-3281	were	_
18-4	3282-3290	assessed	_
18-5	3291-3294	via	_
18-6	3295-3298	The	_
18-7	3299-3312	Simpson-Angus	http://maven.renci.org/NeuroBridge/neurobridge#SimpsonAngusScale
18-8	3313-3318	Scale	http://maven.renci.org/NeuroBridge/neurobridge#SimpsonAngusScale
18-9	3319-3320	(	http://maven.renci.org/NeuroBridge/neurobridge#SimpsonAngusScale
18-10	3321-3324	SAS	http://maven.renci.org/NeuroBridge/neurobridge#SimpsonAngusScale
18-11	3325-3326	)	http://maven.renci.org/NeuroBridge/neurobridge#SimpsonAngusScale
18-12	3327-3328	,	_
18-13	3329-3336	general	_
18-14	3337-3344	medical	_
18-15	3345-3351	burden	_
18-16	3352-3355	via	_
18-17	3356-3359	the	_
18-18	3360-3370	Cumulative	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
18-19	3371-3378	Illness	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
18-20	3379-3385	Rating	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
18-21	3386-3391	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
18-22	3392-3393	–	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
18-23	3394-3404	Geriatrics	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
18-24	3405-3406	(	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
18-25	3407-3412	CIRSG	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
18-26	3413-3414	)	http://maven.renci.org/NeuroBridge/neurobridge#BriefPsychiatricRatingScale
18-27	3415-3418	and	_
18-28	3419-3432	antipsychotic	_
18-29	3433-3443	medication	_
18-30	3444-3452	exposure	_
18-31	3453-3456	via	_
18-32	3457-3471	chlorpromazine	_
18-33	3472-3483	equivalents	_
18-34	3484-3485	.	_

19-1	3486-3489	All	_
19-2	3490-3495	sites	_
19-3	3496-3500	used	_
19-4	3501-3507	weekly	_
19-5	3508-3515	phantom	_
19-6	3516-3521	scans	_
19-7	3522-3524	to	_
19-8	3525-3531	ensure	_
19-9	3532-3535	the	_
19-10	3536-3545	stability	_
19-11	3546-3548	of	_
19-12	3549-3552	the	_
19-13	3553-3564	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
19-14	3565-3566	,	_
19-15	3567-3570	DTI	http://maven.renci.org/NeuroBridge/neurobridge#DifffusionTensorImaging
19-16	3571-3572	,	_
19-17	3573-3576	and	_
19-18	3577-3586	EPI-based	_
19-19	3587-3596	sequences	_
19-20	3597-3601	over	_
19-21	3602-3606	time	_
19-22	3607-3608	.	_

20-1	3609-3611	At	_
20-2	3612-3615	all	_
20-3	3616-3621	sites	_
20-4	3622-3623	,	_
20-5	3624-3626	we	_
20-6	3627-3638	implemented	_
20-7	3639-3651	standardized	_
20-8	3652-3661	operating	_
20-9	3662-3671	protocols	_
20-10	3672-3673	(	_
20-11	3674-3678	SOPs	_
20-12	3679-3680	)	_
20-13	3681-3683	to	_
20-14	3684-3692	minimize	_
20-15	3693-3703	inter-site	_
20-16	3704-3712	variance	_
20-17	3713-3715	in	_
20-18	3716-3719	how	_
20-19	3720-3723	the	_
20-20	3724-3728	data	_
20-21	3729-3732	was	_
20-22	3733-3742	collected	_
20-23	3743-3746	and	_
20-24	3747-3750	how	_
20-25	3751-3754	the	_
20-26	3755-3767	participants	_
20-27	3768-3775	behaved	_
20-28	3776-3777	.	_

21-1	3778-3783	These	_
21-2	3784-3788	SOPs	_
21-3	3789-3801	standardized	_
21-4	3802-3805	the	_
21-5	3806-3820	administration	_
21-6	3821-3823	of	_
21-7	3824-3827	all	_
21-8	3828-3830	in	_
21-9	3831-3834	and	_
21-10	3835-3849	out-of-scanner	_
21-11	3850-3855	tasks	_
21-12	3856-3857	.	_

22-1	3858-3860	In	_
22-2	3861-3869	addition	_
22-3	3870-3871	,	_
22-4	3872-3884	participants	_
22-5	3885-3889	were	_
22-6	3890-3897	trained	_
22-7	3898-3900	on	_
22-8	3901-3904	how	_
22-9	3905-3907	to	_
22-10	3908-3919	participate	_
22-11	3920-3922	in	_
22-12	3923-3926	all	_
22-13	3927-3937	in-scanner	_
22-14	3938-3943	tasks	_
22-15	3944-3945	(	_
22-16	3946-3955	including	_
22-17	3956-3959	the	_
22-18	3960-3967	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
22-19	3968-3973	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
22-20	3974-3978	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
22-21	3979-3980	)	_
22-22	3981-3985	with	_
22-23	3986-3993	minimal	_
22-24	3994-3998	head	_
22-25	3999-4005	motion	_
22-26	4006-4007	.	_

23-1	4008-4010	An	_
23-2	4011-4021	in-scanner	_
23-3	4022-4028	camera	_
23-4	4029-4032	was	_
23-5	4033-4037	also	_
23-6	4038-4046	employed	_
23-7	4047-4049	to	_
23-8	4050-4057	monitor	_
23-9	4058-4069	participant	_
23-10	4070-4078	movement	_
23-11	4079-4085	during	_
23-12	4086-4089	all	_
23-13	4090-4095	scans	_
23-14	4096-4097	.	_

24-1	4098-4105	Finally	_
24-2	4106-4107	,	_
24-3	4108-4113	prior	_
24-4	4114-4116	to	_
24-5	4117-4125	analysis	_
24-6	4126-4127	,	_
24-7	4128-4131	all	_
24-8	4132-4137	scans	_
24-9	4138-4142	were	_
24-10	4143-4150	checked	_
24-11	4151-4154	for	_
24-12	4155-4165	sufficient	_
24-13	4166-4173	quality	_
24-14	4174-4176	by	_
24-15	4177-4188	experienced	_
24-16	4189-4197	research	_
24-17	4198-4203	staff	_
24-18	4204-4205	,	_
24-19	4206-4212	making	_
24-20	4213-4216	use	_
24-21	4217-4219	of	_
24-22	4220-4228	in-house	_
24-23	4229-4238	developed	_
24-24	4239-4246	quality	_
24-25	4247-4254	control	_
24-26	4255-4261	system	_
24-27	4262-4265	and	_
24-28	4266-4278	accompanying	_
24-29	4279-4288	dashboard	_
24-30	4289-4290	(	_
24-31	4291-4296	https	_
24-32	4297-4298	:	_
24-33	4299-4326	//github.com/TIGRLab/datman	_
24-34	4327-4328	;	_
24-35	4329-4334	https	_
24-36	4335-4336	:	_
24-37	4337-4367	//github.com/TIGRLab/dashboard	_
24-38	4368-4369	)	_
24-39	4370-4371	.	_

25-1	4372-4379	Quality	_
25-2	4380-4387	control	_
25-3	4388-4396	involved	_
25-4	4397-4401	both	_
25-5	4402-4414	quantitative	_
25-6	4415-4416	(	_
25-7	4417-4421	e.g.	_
25-8	4422-4423	,	_
25-9	4424-4433	framewise	_
25-10	4434-4446	displacement	_
25-11	4447-4448	,	_
25-12	4449-4464	signal-to-noise	_
25-13	4465-4473	measures	_
25-14	4474-4475	)	_
25-15	4476-4479	and	_
25-16	4480-4491	qualitative	_
25-17	4492-4502	monitoring	_
25-18	4503-4504	(	_
25-19	4505-4509	e.g.	_
25-20	4510-4511	,	_
25-21	4512-4521	detecting	_
25-22	4522-4523	‘	_
25-23	4524-4536	sufficiently	_
25-24	4537-4540	bad	_
25-25	4541-4542	’	_
25-26	4543-4551	ghosting	_
25-27	4552-4554	or	_
25-28	4555-4563	blurring	_
25-29	4564-4566	by	_
25-30	4567-4570	eye	_
25-31	4571-4572	)	_
25-32	4573-4574	.	_

26-1	4575-4579	Some	_
26-2	4580-4582	of	_
26-3	4583-4590	results	_
26-4	4591-4604	demonstrating	_
26-5	4605-4615	inter-site	_
26-6	4616-4625	stability	_
26-7	4626-4630	have	_
26-8	4631-4635	been	_
26-9	4636-4646	documented	_
26-10	4647-4649	in	_
26-11	4650-4653	two	_
26-12	4654-4662	recently	_
26-13	4663-4672	published	_
26-14	4673-4679	papers	_
26-15	4680-4681	.	_

27-1	4682-4684	We	_
27-2	4685-4691	report	_
27-3	4692-4704	participants	_
27-4	4705-4708	who	_
27-5	4709-4713	pass	_
27-6	4714-4721	quality	_
27-7	4722-4729	control	_
27-8	4730-4735	after	_
27-9	4736-4746	completing	_
27-10	4747-4748	a	_
27-11	4749-4760	T1-weighted	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
27-12	4761-4764	and	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
27-13	4765-4772	resting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
27-14	4773-4778	state	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
27-15	4779-4780	(	_
27-16	4781-4786	n=164	_
27-17	4787-4788	)	_
27-18	4789-4793	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
27-19	4794-4798	scan	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
27-20	4799-4800	,	_
27-21	4801-4816	imitate/observe	_
27-22	4817-4818	(	_
27-23	4819-4823	n=93	_
27-24	4824-4825	)	_
27-25	4826-4830	task	_
27-26	4831-4832	,	_
27-27	4833-4836	and	_
27-28	4837-4845	empathic	_
27-29	4846-4854	accuracy	_
27-30	4855-4856	(	_
27-31	4857-4862	n=183	_
27-32	4863-4864	)	_
27-33	4865-4869	task	_
27-34	4870-4871	.	_

28-1	4872-4875	All	_
28-2	4876-4881	three	_
28-3	4882-4886	data	_
28-4	4887-4892	types	_
28-5	4893-4897	were	_
28-6	4898-4906	analyzed	_
28-7	4907-4910	via	_
28-8	4911-4923	connectivity	_
28-9	4924-4932	analysis	_
28-10	4933-4934	,	_
28-11	4935-4938	and	_
28-12	4939-4942	the	_
28-13	4943-4946	two	_
28-14	4947-4952	tasks	_
28-15	4953-4957	were	_
28-16	4958-4962	also	_
28-17	4963-4971	analyzed	_
28-18	4972-4977	using	_
28-19	4978-4979	a	_
28-20	4980-4987	general	_
28-21	4988-4994	linear	_
28-22	4995-5000	model	_
28-23	5001-5002	(	_
28-24	5003-5006	GLM	_
28-25	5007-5008	)	_
28-26	5009-5011	to	_
28-27	5012-5018	detect	_
28-28	5019-5023	task	_
28-29	5024-5035	activations	_
28-30	5036-5041	using	_
28-31	5042-5045	the	_
28-32	5046-5054	original	_
28-33	5055-5060	paper	_
28-34	5061-5062	’	_
28-35	5063-5064	s	_
28-36	5065-5072	methods	_
28-37	5073-5074	.	_

29-1	5075-5078	All	_
29-2	5079-5091	connectivity	_
29-3	5092-5096	data	_
29-4	5097-5100	was	_
29-5	5101-5113	preprocessed	_
29-6	5114-5118	with	_
29-7	5119-5129	FreeSurfer	_
29-8	5130-5131	,	_
29-9	5132-5136	AFNI	_
29-10	5137-5138	,	_
29-11	5139-5142	and	_
29-12	5143-5146	FSL	_
29-13	5147-5148	,	_
29-14	5149-5158	including	_
29-15	5159-5164	steps	_
29-16	5165-5167	to	_
29-17	5168-5176	minimize	_
29-18	5177-5180	the	_
29-19	5181-5187	impact	_
29-20	5188-5190	of	_
29-21	5191-5195	head	_
29-22	5196-5202	motion	_
29-23	5203-5211	artifact	_
29-24	5212-5213	(	_
29-25	5214-5218	i.e.	_
29-26	5219-5220	,	_
29-27	5221-5229	nuisance	_
29-28	5230-5239	parameter	_
29-29	5240-5250	regression	_
29-30	5251-5252	,	_
29-31	5253-5261	removing	_
29-32	5262-5273	high-motion	_
29-33	5274-5284	timepoints	_
29-34	5285-5286	,	_
29-35	5287-5296	rejecting	_
29-36	5297-5301	high	_
29-37	5302-5308	motion	_
29-38	5309-5317	subjects	_
29-39	5318-5319	)	_
29-40	5320-5321	.	_

30-1	5322-5326	Both	_
30-2	5327-5332	tasks	_
30-3	5333-5337	also	_
30-4	5338-5348	separately	_
30-5	5349-5358	underwent	_
30-6	5359-5367	standard	_
30-7	5368-5378	task-based	_
30-8	5379-5383	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
30-9	5384-5398	pre-processing	_
30-10	5399-5400	.	_

31-1	5401-5404	For	_
31-2	5405-5417	connectivity	_
31-3	5418-5426	analysis	_
31-4	5427-5428	,	_
31-5	5429-5432	the	_
31-6	5433-5440	Pearson	_
31-7	5441-5442	’	_
31-8	5443-5444	s	_
31-9	5445-5456	correlation	_
31-10	5457-5464	between	_
31-11	5465-5468	the	_
31-12	5469-5473	mean	_
31-13	5474-5484	timeseries	_
31-14	5485-5489	from	_
31-15	5490-5494	each	_
31-16	5495-5501	region	_
31-17	5502-5504	of	_
31-18	5505-5513	interest	_
31-19	5514-5515	(	_
31-20	5516-5519	ROI	_
31-21	5520-5521	)	_
31-22	5522-5524	in	_
31-23	5525-5526	a	_
31-24	5527-5537	268-region	_
31-25	5538-5543	atlas	_
31-26	5544-5547	was	_
31-27	5548-5558	calculated	_
31-28	5559-5562	for	_
31-29	5563-5564	a	_
31-30	5565-5570	total	_
31-31	5571-5573	of	_
31-32	5574-5580	35,778	_
31-33	5581-5589	r-values	_
31-34	5590-5593	per	_
31-35	5594-5605	participant	_
31-36	5606-5607	.	_

32-1	5608-5611	For	_
32-2	5612-5616	task	_
32-3	5617-5628	activations	_
32-4	5629-5630	,	_
32-5	5631-5634	the	_
32-6	5635-5639	mean	_
32-7	5640-5651	t-statistic	_
32-8	5652-5656	from	_
32-9	5657-5661	each	_
32-10	5662-5665	ROI	_
32-11	5666-5669	was	_
32-12	5670-5680	calculated	_
32-13	5681-5684	for	_
32-14	5685-5686	a	_
32-15	5687-5692	total	_
32-16	5693-5695	of	_
32-17	5696-5699	268	_
32-18	5700-5708	t-values	_
32-19	5709-5712	per	_
32-20	5713-5724	participant	_
32-21	5725-5726	.	_

33-1	5727-5730	See	_
33-2	5731-5741	supplement	_
33-3	5742-5745	for	_
33-4	5746-5753	details	_
33-5	5754-5755	.	_

34-1	5756-5759	The	_
34-2	5760-5767	biotype	_
34-3	5768-5776	analysis	_
34-4	5777-5783	groups	_
34-5	5784-5796	participants	_
34-6	5797-5801	with	_
34-7	5802-5809	similar	_
34-8	5810-5815	brain	_
34-9	5816-5837	connectivity/function	_
34-10	5838-5840	in	_
34-11	5841-5848	regions	_
34-12	5849-5859	associated	_
34-13	5860-5864	with	_
34-14	5865-5868	the	_
34-15	5869-5874	SC/NC	_
34-16	5875-5884	variables	_
34-17	5885-5886	.	_

35-1	5887-5892	First	_
35-2	5893-5894	,	_
35-3	5895-5897	we	_
35-4	5898-5903	found	_
35-5	5904-5905	a	_
35-6	5906-5921	low-dimensional	_
35-7	5922-5936	representation	_
35-8	5937-5939	of	_
35-9	5940-5960	cognitively-relevant	_
35-10	5961-5966	brain	_
35-11	5967-5995	connections/task-activations	_
35-12	5996-5997	(	_
35-13	5998-6005	defined	_
35-14	6006-6010	here	_
35-15	6011-6013	by	_
35-16	6014-6017	the	_
35-17	6018-6020	12	_
35-18	6021-6026	SC/NC	_
35-19	6027-6036	variables	_
35-20	6037-6038	)	_
35-21	6039-6044	using	_
35-22	6045-6054	canonical	_
35-23	6055-6066	correlation	_
35-24	6067-6075	analysis	_
35-25	6076-6077	(	_
35-26	6078-6081	CCA	_
35-27	6082-6083	)	_
35-28	6084-6085	,	_
35-29	6086-6091	which	_
35-30	6092-6094	is	_
35-31	6095-6099	then	_
35-32	6100-6109	clustered	_
35-33	6110-6111	(	_
35-34	6112-6124	hierarchical	_
35-35	6125-6130	using	_
35-36	6131-6135	Ward	_
35-37	6136-6137	’	_
35-38	6138-6139	s	_
35-39	6140-6146	method	_
35-40	6147-6148	)	_
35-41	6149-6153	into	_
35-42	6154-6160	groups	_
35-43	6161-6163	of	_
35-44	6164-6176	participants	_
35-45	6177-6181	with	_
35-46	6182-6189	similar	_
35-47	6190-6195	brain	_
35-48	6196-6217	connectivity/function	_
35-49	6218-6220	in	_
35-50	6221-6228	regions	_
35-51	6229-6239	associated	_
35-52	6240-6244	with	_
35-53	6245-6248	the	_
35-54	6249-6258	cognitive	_
35-55	6259-6267	variable	_
35-56	6268-6270	of	_
35-57	6271-6279	interest	_
35-58	6280-6281	.	_

36-1	6282-6287	Group	_
36-2	6288-6299	differences	_
36-3	6300-6302	in	_
36-4	6303-6308	brain	_
36-5	6309-6330	connectivity/function	_
36-6	6331-6338	between	_
36-7	6339-6347	biotypes	_
36-8	6348-6352	were	_
36-9	6353-6363	calculated	_
36-10	6364-6365	(	_
36-11	6366-6367	q	_
36-12	6368-6369	[	_
36-13	6370-6373	FDR	_
36-14	6374-6375	]	_
36-15	6376-6381	=0.05	_
36-16	6382-6383	)	_
36-17	6384-6386	to	_
36-18	6387-6396	visualize	_
36-19	6397-6402	these	_
36-20	6403-6410	regions	_
36-21	6411-6412	.	_

37-1	6413-6416	See	_
37-2	6417-6427	supplement	_
37-3	6428-6431	for	_
37-4	6432-6439	details	_
37-5	6440-6441	.	_

38-1	6442-6444	We	_
38-2	6445-6451	ranked	_
38-3	6452-6455	the	_
38-4	6456-6463	utility	_
38-5	6464-6466	of	_
38-6	6467-6471	each	_
38-7	6472-6476	fMRI	_
38-8	6477-6482	input	_
38-9	6483-6484	(	_
38-10	6485-6492	resting	_
38-11	6493-6498	state	_
38-12	6499-6500	,	_
38-13	6501-6516	imitate/observe	_
38-14	6517-6518	,	_
38-15	6519-6522	and	_
38-16	6523-6531	empathic	_
38-17	6532-6540	accuracy	_
38-18	6541-6542	)	_
38-19	6543-6546	and	_
38-20	6547-6555	analysis	_
38-21	6556-6562	method	_
38-22	6563-6564	(	_
38-23	6565-6577	connectivity	_
38-24	6578-6581	vs.	_
38-25	6582-6586	task	_
38-26	6587-6598	activations	_
38-27	6599-6600	)	_
38-28	6601-6603	by	_
38-29	6604-6613	comparing	_
38-30	6614-6619	SC/NC	_
38-31	6620-6626	scores	_
38-32	6627-6634	between	_
38-33	6635-6643	biotypes	_
38-34	6644-6645	.	_

39-1	6646-6648	We	_
39-2	6649-6658	validated	_
39-3	6659-6662	our	_
39-4	6663-6671	biotypes	_
39-5	6672-6674	by	_
39-6	6675-6684	comparing	_
39-7	6685-6695	functional	_
39-8	6696-6703	outcome	_
39-9	6704-6707	and	_
39-10	6708-6715	symptom	_
39-11	6716-6722	burden	_
39-12	6723-6729	scores	_
39-13	6730-6731	,	_
39-14	6732-6737	which	_
39-15	6738-6742	were	_
39-16	6743-6746	not	_
39-17	6747-6755	included	_
39-18	6756-6758	in	_
39-19	6759-6762	the	_
39-20	6763-6771	original	_
39-21	6772-6780	analysis	_
39-22	6781-6782	.	_

40-1	6783-6786	For	_
40-2	6787-6790	all	_
40-3	6791-6796	SC/NC	_
40-4	6797-6808	comparisons	_
40-5	6809-6810	,	_
40-6	6811-6813	we	_
40-7	6814-6823	conducted	_
40-8	6824-6825	a	_
40-9	6826-6832	series	_
40-10	6833-6835	of	_
40-11	6836-6843	t-tests	_
40-12	6844-6846	to	_
40-13	6847-6855	contrast	_
40-14	6856-6859	the	_
40-15	6860-6864	mean	_
40-16	6865-6870	score	_
40-17	6871-6873	of	_
40-18	6874-6878	each	_
40-19	6879-6884	group	_
40-20	6885-6890	after	_
40-21	6891-6900	Z-scoring	_
40-22	6901-6908	against	_
40-23	6909-6912	the	_
40-24	6913-6921	controls	_
40-25	6922-6923	.	_

41-1	6924-6934	Functional	_
41-2	6935-6942	outcome	_
41-3	6943-6946	and	_
41-4	6947-6954	symptom	_
41-5	6955-6961	burden	_
41-6	6962-6968	scores	_
41-7	6969-6973	were	_
41-8	6974-6982	Z-scored	_
41-9	6983-6986	and	_
41-10	6987-6995	analyzed	_
41-11	6996-7001	using	_
41-12	7002-7006	only	_
41-13	7007-7011	SSDs	_
41-14	7012-7013	.	_

42-1	7014-7017	All	_
42-2	7018-7023	tests	_
42-3	7024-7028	were	_
42-4	7029-7038	corrected	_
42-5	7039-7042	for	_
42-6	7043-7051	multiple	_
42-7	7052-7063	comparisons	_
42-8	7064-7069	using	_
42-9	7070-7075	false	_
42-10	7076-7085	discovery	_
42-11	7086-7090	rate	_
42-12	7091-7092	(	_
42-13	7093-7094	q	_
42-14	7095-7096	[	_
42-15	7097-7100	FDR	_
42-16	7101-7102	]	_
42-17	7103-7108	=0.05	_
42-18	7109-7110	)	_
42-19	7111-7112	.	_

43-1	7113-7115	We	_
43-2	7116-7123	further	_
43-3	7124-7133	validated	_
43-4	7134-7137	our	_
43-5	7138-7146	biotypes	_
43-6	7147-7152	using	_
43-7	7153-7157	both	_
43-8	7158-7176	FreeSurfer-derived	_
43-9	7177-7185	cortical	_
43-10	7186-7195	thickness	_
43-11	7196-7199	and	_
43-12	7200-7211	subcortical	_
43-13	7212-7219	volumes	_
43-14	7220-7221	,	_
43-15	7222-7224	as	_
43-16	7225-7229	well	_
43-17	7230-7232	as	_
43-18	7233-7244	tract-based	_
43-19	7245-7252	spatial	_
43-20	7253-7271	statistics-derived	_
43-21	7272-7282	fractional	_
43-22	7283-7293	anisotropy	_
43-23	7294-7295	(	_
43-24	7296-7298	FA	_
43-25	7299-7300	)	_
43-26	7301-7304	and	_
43-27	7305-7309	mean	_
43-28	7310-7321	diffusivity	_
43-29	7322-7323	(	_
43-30	7324-7326	MD	_
43-31	7327-7328	)	_
43-32	7329-7330	.	_

44-1	7331-7334	See	_
44-2	7335-7345	supplement	_
44-3	7346-7349	for	_
44-4	7350-7357	details	_
44-5	7358-7359	.	_

45-1	7360-7362	We	_
45-2	7363-7371	assessed	_
45-3	7372-7375	the	_
45-4	7376-7388	relationship	_
45-5	7389-7396	between	_
45-6	7397-7400	the	_
45-7	7401-7405	fMRI	_
45-8	7406-7414	features	_
45-9	7415-7418	and	_
45-10	7419-7426	defined	_
45-11	7427-7433	groups	_
45-12	7434-7435	(	_
45-13	7436-7444	biotypes	_
45-14	7445-7446	,	_
45-15	7447-7456	cognitive	_
45-16	7457-7468	score-based	_
45-17	7469-7470	,	_
45-18	7471-7473	or	_
45-19	7474-7489	diagnosis-based	_
45-20	7490-7491	)	_
45-21	7492-7494	by	_
45-22	7495-7503	training	_
45-23	7504-7505	a	_
45-24	7506-7512	linear	_
45-25	7513-7516	SVC	_
45-26	7517-7518	(	_
45-27	7519-7524	using	_
45-28	7525-7532	10-fold	_
45-29	7533-7538	cross	_
45-30	7539-7549	validation	_
45-31	7550-7551	)	_
45-32	7552-7554	to	_
45-33	7555-7562	predict	_
45-34	7563-7566	the	_
45-35	7567-7572	group	_
45-36	7573-7575	of	_
45-37	7576-7584	held-out	_
45-38	7585-7597	participants	_
45-39	7598-7599	(	_
45-40	7600-7608	test-set	_
45-41	7609-7610	)	_
45-42	7611-7616	using	_
45-43	7617-7620	the	_
45-44	7621-7625	fMRI	_
45-45	7626-7634	features	_
45-46	7635-7639	from	_
45-47	7640-7641	a	_
45-48	7642-7650	training	_
45-49	7651-7654	set	_
45-50	7655-7656	.	_

46-1	7657-7661	Each	_
46-2	7662-7668	column	_
46-3	7669-7671	of	_
46-4	7672-7675	the	_
46-5	7676-7680	fMRI	_
46-6	7681-7686	input	_
46-7	7687-7693	matrix	_
46-8	7694-7697	was	_
46-9	7698-7706	Z-scored	_
46-10	7707-7713	before	_
46-11	7714-7722	training	_
46-12	7723-7724	.	_

47-1	7725-7728	For	_
47-2	7729-7732	all	_
47-3	7733-7747	classification	_
47-4	7748-7756	analyses	_
47-5	7757-7766	conducted	_
47-6	7767-7771	with	_
47-7	7772-7786	biotype-groups	_
47-8	7787-7788	,	_
47-9	7789-7792	CCA	_
47-10	7793-7796	and	_
47-11	7797-7807	clustering	_
47-12	7808-7811	was	_
47-13	7812-7821	performed	_
47-14	7822-7824	on	_
47-15	7825-7828	the	_
47-16	7829-7837	training	_
47-17	7838-7841	set	_
47-18	7842-7847	alone	_
47-19	7848-7851	for	_
47-20	7852-7856	each	_
47-21	7857-7861	fold	_
47-22	7862-7863	,	_
47-23	7864-7866	to	_
47-24	7867-7874	prevent	_
47-25	7875-7878	any	_
47-26	7879-7890	information	_
47-27	7891-7898	sharing	_
47-28	7899-7906	between	_
47-29	7907-7910	the	_
47-30	7911-7919	training	_
47-31	7920-7923	and	_
47-32	7924-7928	test	_
47-33	7929-7932	set	_
47-34	7933-7934	.	_

48-1	7935-7938	The	_
48-2	7939-7943	mean	_
48-3	7944-7952	accuracy	_
48-4	7953-7954	,	_
48-5	7955-7961	recall	_
48-6	7962-7963	,	_
48-7	7964-7973	precision	_
48-8	7974-7975	,	_
48-9	7976-7978	f1	_
48-10	7979-7984	score	_
48-11	7985-7986	(	_
48-12	7987-7995	harmonic	_
48-13	7996-8000	mean	_
48-14	8001-8003	of	_
48-15	8004-8013	precision	_
48-16	8014-8017	and	_
48-17	8018-8024	recall	_
48-18	8025-8026	)	_
48-19	8027-8028	,	_
48-20	8029-8032	and	_
48-21	8033-8037	area	_
48-22	8038-8043	under	_
48-23	8044-8047	the	_
48-24	8048-8053	curve	_
48-25	8054-8056	of	_
48-26	8057-8060	the	_
48-27	8061-8069	receiver	_
48-28	8070-8078	operator	_
48-29	8079-8093	characteristic	_
48-30	8094-8095	(	_
48-31	8096-8099	AUC	_
48-32	8100-8101	)	_
48-33	8102-8105	was	_
48-34	8106-8116	calculated	_
48-35	8117-8123	across	_
48-36	8124-8127	all	_
48-37	8128-8133	folds	_
48-38	8134-8135	.	_

49-1	8136-8139	For	_
49-2	8140-8143	all	_
49-3	8144-8159	cognitive-score	_
49-4	8160-8165	based	_
49-5	8166-8171	group	_
49-6	8172-8180	analyses	_
49-7	8181-8182	,	_
49-8	8183-8185	we	_
49-9	8186-8191	split	_
49-10	8192-8204	participants	_
49-11	8205-8209	into	_
49-12	8210-8211	a	_
49-13	8212-8218	normal	_
49-14	8219-8222	and	_
49-15	8223-8240	poorly-performing	_
49-16	8241-8246	group	_
49-17	8247-8252	based	_
49-18	8253-8255	on	_
49-19	8256-8257	a	_
49-20	8258-8268	percentile	_
49-21	8269-8274	split	_
49-22	8275-8277	of	_
49-23	8278-8281	the	_
49-24	8282-8287	first	_
49-25	8288-8297	principal	_
49-26	8298-8307	component	_
49-27	8308-8310	of	_
49-28	8311-8314	the	_
49-29	8315-8317	12	_
49-30	8318-8323	SC/NC	_
49-31	8324-8330	scores	_
49-32	8331-8332	.	_

50-1	8333-8335	We	_
50-2	8336-8340	took	_
50-3	8341-8361	diagnosis-prediction	_
50-4	8362-8373	performance	_
50-5	8374-8376	as	_
50-6	8377-8385	baseline	_
50-7	8386-8387	.	_

51-1	8388-8391	See	_
51-2	8392-8398	figure	_
51-3	8399-8401	s1	_
51-4	8402-8405	for	_
51-5	8406-8408	an	_
51-6	8409-8417	overview	_
51-7	8418-8419	,	_
51-8	8420-8423	and	_
51-9	8424-8434	supplement	_
51-10	8435-8438	for	_
51-11	8439-8446	details	_
51-12	8447-8448	.	_

52-1	8449-8451	To	_
52-2	8452-8456	rank	_
52-3	8457-8460	the	_
52-4	8461-8468	utility	_
52-5	8469-8471	of	_
52-6	8472-8475	the	_
52-7	8476-8480	fMRI	_
52-8	8481-8489	features	_
52-9	8490-8491	,	_
52-10	8492-8494	we	_
52-11	8495-8503	compared	_
52-12	8504-8509	their	_
52-13	8510-8517	ability	_
52-14	8518-8520	to	_
52-15	8521-8526	split	_
52-16	8527-8530	the	_
52-17	8531-8537	sample	_
52-18	8538-8542	into	_
52-19	8543-8549	groups	_
52-20	8550-8554	with	_
52-21	8555-8560	large	_
52-22	8561-8566	SC/NC	_
52-23	8567-8572	score	_
52-24	8573-8584	differences	_
52-25	8585-8588	via	_
52-26	8589-8592	the	_
52-27	8593-8601	t-scores	_
52-28	8602-8610	computed	_
52-29	8611-8620	comparing	_
52-30	8621-8626	SC/NC	_
52-31	8627-8633	scores	_
52-32	8634-8641	between	_
52-33	8642-8650	biotypes	_
52-34	8651-8652	(	_
52-35	8653-8655	we	_
52-36	8656-8662	report	_
52-37	8663-8666	the	_
52-38	8667-8671	mean	_
52-39	8672-8673	t	_
52-40	8674-8683	statistic	_
52-41	8684-8690	across	_
52-42	8691-8694	the	_
52-43	8695-8697	12	_
52-44	8698-8703	SC/NC	_
52-45	8704-8710	scores	_
52-46	8711-8719	assessed	_
52-47	8720-8727	between	_
52-48	8728-8734	groups	_
52-49	8735-8737	in	_
52-50	8738-8742	each	_
52-51	8743-8747	case	_
52-52	8748-8749	)	_
52-53	8750-8751	,	_
52-54	8752-8755	and	_
52-55	8756-8761	their	_
52-56	8762-8773	performance	_
52-57	8774-8778	when	_
52-58	8779-8783	used	_
52-59	8784-8786	to	_
52-60	8787-8792	train	_
52-61	8793-8794	a	_
52-62	8795-8798	SVC	_
52-63	8799-8801	to	_
52-64	8802-8809	predict	_
52-65	8810-8813	the	_
52-66	8814-8821	biotype	_
52-67	8822-8824	of	_
52-68	8825-8833	held-out	_
52-69	8834-8846	participants	_
52-70	8847-8850	via	_
52-71	8851-8854	the	_
52-72	8855-8859	mean	_
52-73	8860-8868	test-set	_
52-74	8869-8872	AUC	_
52-75	8873-8881	computed	_
52-76	8882-8888	during	_
52-77	8889-8905	cross-validation	_
52-78	8906-8907	.	_

53-1	8908-8912	Each	_
53-2	8913-8920	biotype	_
53-3	8921-8926	model	_
53-4	8927-8931	must	_
53-5	8932-8939	surpass	_
53-6	8940-8948	baseline	_
53-7	8949-8954	SC/NC	_
53-8	8955-8960	score	_
53-9	8961-8972	differences	_
53-10	8973-8980	between	_
53-11	8981-8991	diagnostic	_
53-12	8992-8998	groups	_
53-13	8999-9001	to	_
53-14	9002-9004	be	_
53-15	9005-9015	considered	_
53-16	9016-9022	useful	_
53-17	9023-9024	.	_

54-1	9025-9030	While	_
54-2	9031-9036	SC/NC	_
54-3	9037-9042	score	_
54-4	9043-9054	differences	_
54-5	9055-9062	between	_
54-6	9063-9071	biotypes	_
54-7	9072-9075	are	_
54-8	9076-9084	expected	_
54-9	9085-9090	given	_
54-10	9091-9095	that	_
54-11	9096-9099	CCA	_
54-12	9100-9108	selected	_
54-13	9109-9113	fMRI	_
54-14	9114-9122	features	_
54-15	9123-9127	with	_
54-16	9128-9129	a	_
54-17	9130-9136	strong	_
54-18	9137-9149	relationship	_
54-19	9150-9152	to	_
54-20	9153-9156	the	_
54-21	9157-9162	SC/NC	_
54-22	9163-9164	,	_
54-23	9165-9168	the	_
54-24	9169-9178	magnitude	_
54-25	9179-9181	of	_
54-26	9182-9185	the	_
54-27	9186-9199	between-group	_
54-28	9200-9211	differences	_
54-29	9212-9218	should	_
54-30	9219-9227	modulate	_
54-31	9228-9237	depending	_
54-32	9238-9240	on	_
54-33	9241-9244	the	_
54-34	9245-9253	strength	_
54-35	9254-9256	of	_
54-36	9257-9261	that	_
54-37	9262-9274	relationship	_
54-38	9275-9276	.	_

55-1	9277-9279	We	_
55-2	9280-9284	then	_
55-3	9285-9294	attempted	_
55-4	9295-9297	to	_
55-5	9298-9307	replicate	_
55-6	9308-9311	our	_
55-7	9312-9316	main	_
55-8	9317-9321	fMRI	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
55-9	9322-9330	findings	_
55-10	9331-9333	an	_
55-11	9334-9345	independent	_
55-12	9346-9352	sample	_
55-13	9353-9355	of	_
55-14	9356-9358	75	_
55-15	9359-9371	participants	_
55-16	9372-9375	who	_
55-17	9376-9385	completed	_
55-18	9386-9389	the	_
55-19	9390-9397	resting	_
55-20	9398-9403	state	_
55-21	9404-9407	and	_
55-22	9408-9423	imitate/observe	_
55-23	9424-9429	tasks	_
55-24	9430-9431	;	_
55-25	9432-9435	see	_
55-26	9436-9446	supplement	_
55-27	9447-9450	for	_
55-28	9451-9458	details	_
55-29	9459-9460	.	_

56-1	9461-9464	The	_
56-2	9465-9473	analysis	_
56-3	9474-9478	code	_
56-4	9479-9481	is	_
56-5	9482-9490	packaged	_
56-6	9491-9493	as	_
56-7	9494-9495	a	_
56-8	9496-9512	freely-available	_
56-9	9513-9517	tool	_
56-10	9518-9519	‘	_
56-11	9520-9526	xbrain	_
56-12	9527-9528	’	_
56-13	9529-9530	(	_
56-14	9531-9567	www.github.com/josephdviviano/xbrain	_
56-15	9568-9569	)	_
56-16	9570-9571	,	_
56-17	9572-9575	and	_
56-18	9576-9579	the	_
56-19	9580-9589	follow-up	_
56-20	9590-9597	scripts	_
56-21	9598-9602	used	_
56-22	9603-9605	to	_
56-23	9606-9613	analyze	_
56-24	9614-9617	the	_
56-25	9618-9625	outputs	_
56-26	9626-9628	of	_
56-27	9629-9635	xbrain	_
56-28	9636-9639	can	_
56-29	9640-9642	be	_
56-30	9643-9648	found	_
56-31	9649-9653	here	_
56-32	9654-9655	(	_
56-33	9656-9693	www.github.com/josephdviviano/biotype	_
56-34	9694-9695	)	_
56-35	9696-9697	.	_

